Antifungal Efficacy of Chitosan-Stabilized Biogenic Silver Nanoparticles against Pathogenic Candida spp. Isolated from H
- PDF / 986,466 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 4 Downloads / 228 Views
Antifungal Efficacy of Chitosan-Stabilized Biogenic Silver Nanoparticles against Pathogenic Candida spp. Isolated from Human Smitha Vijayan 1
&
K. Divya 1 & Sherin Varghese 1 & M. S. Jisha 1
# Springer Science+Business Media, LLC, part of Springer Nature 2020
Abstract Biogenic silver nanoparticles (Bio-AgNPs) have been recognized to play a major role in the fight against multi-drug-resistant pathogens. The present study evaluates antifungal efficacy of biogenic AgNPs conjugated with a natural polymer chitosan (derived from shrimp (Penaeus monodon) shells). Bio-AgNPs used for conjugation were produced by a mycoendophyte Colletotrichum gloeosporioides (KX881911) isolated from the medicinal plant Withania somnifera (L.). During the last decade, although numerous reports on Bio-AgNPs with antimicrobial activity have been reported, insights on the usage of conjugates of Bio-AgNPs have been scarce. Candida species are responsible for severe nosocomial infections and which has developed resistance against many antifungal agents. The current study aims to evaluate the antifungal activity of Bio-AgNPs conjugated with chitosan (Ch Bio-AgNPs) on various Candida species isolated from patients. The fungicidal activity was screened by well diffusion assay and TTC assay. Antibiofilm activity against Candida species was well elucidated by Congo red agar and Crystal Violet assay. Ch Bio-AgNPs showed the potent antifungal effect at 50 μg/ml concentration on all the selected Candida species, and the disruption and distortion of cells were documented well with transmission electron microscopy (TEM). The TEM images showed adhesion and entry of Ch Bio-AgNPs into the cells and release of cellular inclusions along with cell damage and distorted cell morphology. To conclude, the study suggests that Ch Bio-AgNP is a potential antifungal agent to treat drug-resistant pathogenic Candida species. Keywords Ch Bio-AgNPs . Withania somnifera (L.) . Antifungal activity . Candida species . TTC assay . Antibiofilm
1 Introduction In the health care settings, fungal infections are a major problem and it increased the morbidity and mortality of immunocompromised patients. Candida spp. are more common among the fungal pathogens and cause major invasive bloodstream infections. The blooming antifungal resistance among the Candida spp. makes them harder to treat. Some Candida
* M. S. Jisha [email protected] Smitha Vijayan [email protected] K. Divya [email protected] Sherin Varghese [email protected] 1
Research Scholar, School of Biosciences, Mahatma Gandhi University, Kottayam, Kerala, India
sp. already developed resistance towards the first-line and second-line antifungal agents. More than 70% of Candida albicans, Candida glabrata, and Candida krusei showed resistance towards antifungal agents, and they are major agents causing bloodstream infections [1]. The capacity to form biofilms on the inert and biological surface is the important factor which makes them more pathogenic [2]. To overcome the new threat of growing antibiotic re
Data Loading...
